media – Page 33 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

A Rehearsal for Overcoming AIDS

Starting in June 2024, global scholars concerned with HIV prevention will focus their attention on Gilead’s antiviral drug, lenacapavir. At that time, Gilead released the latest data from the PURPOSE 1 trial, which demonstrated that lenacapavir, when administered via two annual injections, resulted in zero infections compared to daily oral PrEP medications. This suggests that, in the absence of successful vaccine development, lenacapavir could potentially serve as a long-lasting preventive alternative. However, whether the results of the PURPOSE 1 trial were a coincidence or a certainty remains unanswered. In September, Gilead further presented results from the PURPOSE 2 trial, indicating a higher likelihood of certainty. The results showed that 99.9% of participants in the lenacapavir group did not contract HIV, representing a 96% reduction in infection risk compared to the placebo group. This might signal that we are approaching an era of highly effective HIV prevention. 01 / The ...
- Source: https://caifuhao.eastmoney.com/news/20240925115315100512370?from=guba&name=5YyW5a2m5Yi26I2v5ZCn&gubaurl=aHR0cHM6Ly9ndWJhLmVhc3Rtb25leS5jb20vbGlzdCxiazA0NjUsOTksai5odG1s
- 71
- October 1, 2024
Medexpo Tanzania

Organiser：EXPOGROUP Time：October 9 – 11, 2024 Address：Aga Khan Diamond Jubilee Hall, P.O.Box 7750, Malik Road, Upanga West, Dar es Salaam, Tanzania Exhibition hall：Aga Khan Diamond Jubilee Hall Product range: Hospital Equipment & Supplies: Patient Rehabilitation & Wellness Services, Hospital Furniture & Management, IT & Telecommunication, Ambulances & Transportation Equipment, Surgical Gowns, Medical Consumables, Water Treatment Equipment, Cleaning Equipment & Services, Biotechnology, etc. Medical Devices & Laboratory Equipment: Respiratory Devices, Imaging Equipment, Surgical Instruments & Supplies, Diagnostic Equipment & Instruments, Dialysis Equipment, EEG & ECG Machines, Endoscopes & Accessories, UV & IR Radiation Equipment, Thermotherapy Devices, Ultrasound Diagnostic Equipment, Heating Systems, Cardiac Catheterization Equipment, Medical Lighting Products, MRI Scanners, Oxygen Supply Equipment, Sterilization & Disinfection Equipment, Urinary Catheters, Colposcopes, Disposable Items, Cryosurgical Equipment, Laser Surgical Equipment, Laser Therapy Devices, Lithotripsy Machines, Laboratory Equipment & Supplies, etc. Dental Equipment: Dental Tools, Equipment, Surgical Instruments, Dental Care Products & Medicines, Artificial Teeth ...
- Source: drugdu
- 93
- October 1, 2024
Merck’s first GMP grade cell culture medium production line in China has been commercialized and put into operation

Merck, a globally leading technology company, announced on July 12th that it has successfully commercialized its first GMP grade cell culture medium (CCM) production line in China. Merck has invested approximately 6.6 million euros in its manufacturing base located in Nantong, an industrial hub in the Yangtze River Delta region, in an effort to meet the growing demand in the Chinese market for high-quality customized cell culture media (used in fields such as biopharmaceuticals, vaccines, and new therapies). This localized commercial production can enable Chinese customers to reliably and efficiently obtain Merck’s highly reputable customized cell culture medium products and services. With its rich and professional formula experience and knowledge, Merck can produce high-quality customized cell culture media and innovative solutions based on specific formulas, ensuring batch uniformity and production efficiency of products. Merck Life Sciences China Managing Director Wu Bo said, “This investment further expands Merck’s business territory and ...
- Source: drugdu
- 107
- September 30, 2024
Jianjia Robot applies to withdraw its IPO application documents

On September 26th, the Shanghai Stock Exchange announced that Hangzhou Jianjia Robot Technology Co., Ltd. (hereinafter referred to as Jianjia Medical) has applied to withdraw its application for listing and therefore decided to terminate the review of its public offering of shares and listing on the Science and Technology Innovation Board. It is reported that Jianjia Robot applied for an IPO on the Science and Technology Innovation Board on April 2, 2023. After a round of inquiries, the Shanghai Stock Exchange reviewed and focused on issues such as orthopedic and dental implant surgical robots, market space, and core technologies. It takes one and a half years from application to termination. Yesterday, Jianjia Robot terminated its IPO, and another equipment company’s attempt to go public failed. The winter of IPO for equipment companies continues. When will spring come? Jianjia Robot has great potential for the future Jianjia Robot was founded in ...
- Source: drugdu
- 102
- September 30, 2024
【EXPERT Q&A】What is the latest development of FIC drugs?

Drugdu.com expert’s response: FIC (First-in-class) drugs, as their name implies, are the first medications of their kind with entirely novel and unique mechanisms of action, pioneering the treatment of specific diseases. Their latest advancements can be outlined from several perspectives: Ⅰ. Overview of FIC Drugs Globally and in China Global Scope: According to publicly available information, the FDA approved a total of 55 new drugs in 2023, among which 20 were FIC drugs, accounting for 36% of the total. This underscores the pivotal role of FIC drugs in the global drug discovery and development landscape. Chinese Scope: Chinese enterprises are increasingly focusing on innovative drugs. In 2023, 30 of the newly approved drugs in China were developed domestically, constituting 37% of the overall approvals. Furthermore, Chinese scholars’ publications in authoritative journals indicate a significant increase in the total number of innovative products in China’s pipeline, with FIC products growing from ...
- Source: drugdu
- 80
- September 30, 2024
What Are Its Treatment Prospects?

Recently, according to publicly available information from the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the technetium-99m ([99mTc]) hydrazinonicotinamide polyethylene glycol RGD peptide injection (referred to as “99mTc-3PRGD2”) developed by Ruidiao Pharmaceuticals has been included in the priority review list. This also applies to the injection of toluenesulfonate hydrazone nicotinamide polyethylene glycol RGD peptide. 99mTc-3PRGD2 is a radiolabeled drug conjugate (RDC) independently developed by Ruidiao Pharmaceuticals. It is the first class I new drug for radiologic diagnosis in nuclear medicine in China and the world’s first broad-spectrum tumor imaging agent for SPECT imaging. Notably, the success of this drug’s development will change the current technical status and conventional understanding that SPECT/CT imaging technology in nuclear medicine cannot be used for tumor diagnosis, staging, and efficacy evaluation. According to Ruidiao Pharmaceuticals, 99mTc-3PRGD2 targets integrin and specifically binds to the integrin αvβ3 receptor on tumor neovascularization, demonstrating high ...
- Source: drugdu
- 85
- September 30, 2024
The second half of the battle to defend the Medicine King

Recently, Astellas announced that Japan’s MHLW has approved its ADC drug ennozumab PADCEV and Merck’s K drug as a first-line combination therapy for adult patients with fundamentally unresectable urothelial cancer. With excellent data, this combination treatment regimen was approved by the Japanese MHLW in such a short time after Merck announced on September 4 that it had been approved by the European Commission (EC) as a first-line therapy. However, sporadic victories cannot conceal the plight of K-drugs. For the pharmaceutical industry, the biggest hot spot in the past two weeks is definitely the announcement by Kangfang Biologics on September 8 that ivocilimab has become the world’s first and only single-drug head-to-head phase III clinical study to prove that its efficacy is significantly better than that of pabrolib. The drug Zizumab. On the day the results were announced, Merck’s stock price fell in response, and the dilemma was obvious. Under the ...
- Source: drugdu
- 87
- September 30, 2024
A historic night in the treatment of schizophrenia

On September 26, the field of schizophrenia ushered in a historic moment, when KarXT developed by Karuna was approved by the FDA for marketing. This means that Bristol-Myers Squibb’s tens of billions of bets have succeeded in their first battle. On December 22 last year, Bristol-Myers Squibb spent $14 billion to acquire Karuna for KarXT. KarXT has been approved for marketing, and there is another winner – Zai Lab. Currently, Zai Lab owns the rights to KarXT in Greater China. Considering that there are more than 8 million schizophrenia patients in China, and the introduction cost of Zai Lab is not high, it is expected to obtain sufficient profits. Of course, all this can only be said to have settled, and is not surprising. Most of the existing schizophrenia treatments are old varieties approved in the 1990s. KarXT does not rely on dopaminergic or serotonergic pathways and is the first ...
- Source: drugdu
- 71
- September 30, 2024
From the rise of Sinocell, we can see the first principles of pharmaceutical companies

In the 1950s, George W. Merck, then CEO of Merck, said a widely circulated saying in the pharmaceutical industry: “We should always remember that drugs are produced for humans, not for the pursuit of profits. As long as we stick to this belief, profits will follow.” It is true. Looking at large overseas pharmaceutical companies, the key to their success lies in patient-centeredness and a strong sense of social responsibility. In China, there are more and more such examples. For example, the vision of Sinocell is to focus on the research and development of drugs urgently needed by the people and provide patients with high-quality and affordable biological drugs. It seems to coincide with Merck. On the product side, Sinocell uses technological innovation to provide higher quality and lower cost drugs, which reduces the economic burden of domestic patients, while bringing better treatment effects and achieving a win-win situation of ...
- Source: drugdu
- 80
- September 30, 2024
Fosun Pharma continues to strengthen the research and development of innovative cancer drugs, and will build the most comprehensive cell therapy pipeline in Pudong

Cell therapy brings a paradigm revolution that can bring hope for a cure to cancer patients. The first cell therapy product to be launched is Yikaida ® It’s a good example. Cell therapy is a key focus of Fosun Pharma’s future development During a recent interview with Zhang Wenjie, CEO and Chairman of Fosun Pharma, he stated that Fosun Pharma is focusing on niche markets with broad prospects in the pharmaceutical industry. Just this month, Fosun Pharma announced that it will fully control Fosun Kate, which is planning to be renamed Fosun Carey and will serve as Fosun Pharma’s core platform in the field of cell therapy technology, continuing to focus on the field of tumor immunotherapy. It is reported that Fosun Kate, located in Pudong, is planning to build the strongest and most comprehensive cell therapy pipeline in China and even globally. Building a powerful CAR-T product pipeline In ...
- Source: drugdu
- 94
- September 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.